Skip to content

13F-HR filed by Caligan Partners LP

Caligan Partners LP filed this 13F-HR for the quarter ended 2024-12-31, filed 2025-02-14, with 14 holding rows worth $394,876,202.

Accession
0001420506-25-000624
Filed
2025-02-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2024

A holdings report, 14 entries on the cover page, a total value of $394,876,202 stated on the cover page (in dollars after the unit check, H1), rows summing to $394,876,202 with VALUE read as dollars as filed, 13F file number 028-23096. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
LIQUIDIA CORPORATION COM NEW53635D202Stock8,118,592$115,527,564dollars as filed
VERONA PHARMA PLC925050106SPONSORED ADS1,436,878$66,728,614dollars as filed
EXELIXIS INC COM30161Q104Stock1,525,730$50,806,809dollars as filed
EVOLUS INC30052C107COM2,692,388$29,723,964dollars as filed
ANIKA THERAPEUTICS INC035255108COM1,435,130$23,622,240dollars as filed
BIOCRYST PHARMACEUTICALS INC COM09058V103Stock2,995,932$22,529,409dollars as filed
AGIOS PHARMACEUTICALS INC00847X104COM626,280$20,579,561dollars as filed
SAGE THERAPEUTICS INC78667J108COM3,052,538$16,575,281dollars as filed
Y-mAbs Therapeutics Inc984241109Common Stock1,767,982$13,843,299dollars as filed
MINERALYS THERAPEUTICS INC603170101COM1,011,155$12,447,318dollars as filed
MERUS N VN5749R100COM255,000$10,722,750dollars as filed
ABIVAX SA-00370M103SPONSORED ADS752,167$5,505,862dollars as filed
VERRICA PHARMACEUTICALS INC92511W108COM7,429,687$5,200,781dollars as filed
ENANTA PHARMACEUTICALS INC29251M106COM184,826$1,062,750dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001420506-25-000624this filing2025-02-14acceptance time not in the bulk data set